Publication | Closed Access

Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis

Hematological MalignancyMyelodysplastic SyndromeMedicineMixed-phenotype Acute LeukemiaHematologyImmunologyPathologyAutoimmunityOvert LeukemiaAdult T-cell Leukemia-lymphomaImmunotherapyMolecular DiagnosticsCell TransplantationMyeloid Neoplasia